放射孤立综合征患者开始疾病改良治疗是否能降低其转化为多发性硬化症的风险?一个经过严格评估的话题。

IF 1 4区 医学 Q4 CLINICAL NEUROLOGY
Aimen Vanood, Nicholas L Zalewski, Lisa A Marks, Cumara B O'Carroll, Cristina Valencia Sanchez
{"title":"放射孤立综合征患者开始疾病改良治疗是否能降低其转化为多发性硬化症的风险?一个经过严格评估的话题。","authors":"Aimen Vanood, Nicholas L Zalewski, Lisa A Marks, Cumara B O'Carroll, Cristina Valencia Sanchez","doi":"10.1097/NRL.0000000000000633","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiologically Isolated Syndrome (RIS) is defined as incidentally found MRI abnormalities that are radiographically indistinguishable from multiple sclerosis (MS) and is considered a presymptomatic disease state of MS. Age <37 years, infratentorial or spinal cord lesions, gadolinium-enhancing lesions on index imaging, and positive cerebrospinal fluid oligoclonal bands have been identified as risk factors for conversion to MS. There are no existing guidelines regarding the role of disease-modifying therapy (DMT) in RIS patients.</p><p><strong>Objective: </strong>The objective of this study was to critically assess the current evidence regarding the impact of initiating DMT for patients with RIS on the time to first clinical attack of MS.</p><p><strong>Methods: </strong>The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario with a clinical question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, medical librarian, and content experts in the field of neuroimmunology.</p><p><strong>Results: </strong>A multicenter, prospective, randomized, double-blind, placebo-controlled trial was chosen for critical appraisal. This trial examined the impact of treatment with dimethyl fumarate (DMF) versus placebo on the risk of conversion from RIS to MS over a 96-week study period. Patients in the DMF arm were found to have an 82% reduction in risk of clinical attack. DMF patients also had a smaller number of new/newly enlarging T2 hyperintense lesions compared with placebo. No subgroup analyses were performed to elucidate risk factors for conversion.</p><p><strong>Conclusions: </strong>While initiation of DMT in RIS does appear to reduce the time to first clinical attack of MS, the risk factors that should prompt initiation of DMT in this patient population require further study.</p>","PeriodicalId":49758,"journal":{"name":"Neurologist","volume":" ","pages":"329-333"},"PeriodicalIF":1.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Does Initiation of Disease Modifying Therapy in Patients With Radiologically Isolated Syndrome Reduce their Risk of Conversion to Multiple Sclerosis? A Critically Appraised Topic.\",\"authors\":\"Aimen Vanood, Nicholas L Zalewski, Lisa A Marks, Cumara B O'Carroll, Cristina Valencia Sanchez\",\"doi\":\"10.1097/NRL.0000000000000633\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Radiologically Isolated Syndrome (RIS) is defined as incidentally found MRI abnormalities that are radiographically indistinguishable from multiple sclerosis (MS) and is considered a presymptomatic disease state of MS. Age <37 years, infratentorial or spinal cord lesions, gadolinium-enhancing lesions on index imaging, and positive cerebrospinal fluid oligoclonal bands have been identified as risk factors for conversion to MS. There are no existing guidelines regarding the role of disease-modifying therapy (DMT) in RIS patients.</p><p><strong>Objective: </strong>The objective of this study was to critically assess the current evidence regarding the impact of initiating DMT for patients with RIS on the time to first clinical attack of MS.</p><p><strong>Methods: </strong>The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario with a clinical question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, medical librarian, and content experts in the field of neuroimmunology.</p><p><strong>Results: </strong>A multicenter, prospective, randomized, double-blind, placebo-controlled trial was chosen for critical appraisal. This trial examined the impact of treatment with dimethyl fumarate (DMF) versus placebo on the risk of conversion from RIS to MS over a 96-week study period. Patients in the DMF arm were found to have an 82% reduction in risk of clinical attack. DMF patients also had a smaller number of new/newly enlarging T2 hyperintense lesions compared with placebo. No subgroup analyses were performed to elucidate risk factors for conversion.</p><p><strong>Conclusions: </strong>While initiation of DMT in RIS does appear to reduce the time to first clinical attack of MS, the risk factors that should prompt initiation of DMT in this patient population require further study.</p>\",\"PeriodicalId\":49758,\"journal\":{\"name\":\"Neurologist\",\"volume\":\" \",\"pages\":\"329-333\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/NRL.0000000000000633\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/NRL.0000000000000633","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:放射孤立综合征(RIS)被定义为偶然发现的MRI异常,在放射学上与多发性硬化症(MS)无法区分,被认为是MS的症状前疾病状态。年龄目的:本研究的目的是严格评估RIS患者开始DMT对MS首次临床发作时间的影响的现有证据。该目标是通过制定一个结构化的批判性评估主题来实现的。这包括一个带有临床问题的临床场景、文献检索策略、批判性评价、结果、证据总结、评论和底线结论。参与者包括顾问和住院神经科医生、医学图书管理员和神经免疫学领域的内容专家。结果:我们选择了一项多中心、前瞻性、随机、双盲、安慰剂对照试验进行批判性评价。该试验研究了富马酸二甲酯(DMF)治疗与安慰剂治疗在96周研究期间从RIS转化为MS的风险的影响。DMF组患者的临床发作风险降低了82%。与安慰剂组相比,DMF患者也有更少的新发/新扩大的T2高信号病变。没有进行亚组分析来阐明转化的危险因素。结论:虽然RIS患者开始使用DMT似乎可以缩短MS首次临床发作的时间,但促使该患者群体开始使用DMT的危险因素需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Does Initiation of Disease Modifying Therapy in Patients With Radiologically Isolated Syndrome Reduce their Risk of Conversion to Multiple Sclerosis? A Critically Appraised Topic.

Background: Radiologically Isolated Syndrome (RIS) is defined as incidentally found MRI abnormalities that are radiographically indistinguishable from multiple sclerosis (MS) and is considered a presymptomatic disease state of MS. Age <37 years, infratentorial or spinal cord lesions, gadolinium-enhancing lesions on index imaging, and positive cerebrospinal fluid oligoclonal bands have been identified as risk factors for conversion to MS. There are no existing guidelines regarding the role of disease-modifying therapy (DMT) in RIS patients.

Objective: The objective of this study was to critically assess the current evidence regarding the impact of initiating DMT for patients with RIS on the time to first clinical attack of MS.

Methods: The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario with a clinical question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, medical librarian, and content experts in the field of neuroimmunology.

Results: A multicenter, prospective, randomized, double-blind, placebo-controlled trial was chosen for critical appraisal. This trial examined the impact of treatment with dimethyl fumarate (DMF) versus placebo on the risk of conversion from RIS to MS over a 96-week study period. Patients in the DMF arm were found to have an 82% reduction in risk of clinical attack. DMF patients also had a smaller number of new/newly enlarging T2 hyperintense lesions compared with placebo. No subgroup analyses were performed to elucidate risk factors for conversion.

Conclusions: While initiation of DMT in RIS does appear to reduce the time to first clinical attack of MS, the risk factors that should prompt initiation of DMT in this patient population require further study.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neurologist
Neurologist 医学-临床神经学
CiteScore
1.90
自引率
0.00%
发文量
151
审稿时长
2 months
期刊介绍: The Neurologist publishes articles on topics of current interest to physicians treating patients with neurological diseases. The core of the journal is review articles focusing on clinically relevant issues. The journal also publishes case reports or case series which review the literature and put observations in perspective, as well as letters to the editor. Special features include the popular "10 Most Commonly Asked Questions" and the "Patient and Family Fact Sheet," a handy tear-out page that can be copied to hand out to patients and their caregivers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信